Circumventricular Organ Apelin Receptor Knockdown Decreases Blood Pressure and Sympathetic Drive Responses in the Spontaneously Hypertensive Rat

Philip R. Griffiths¹, Stephen J. Lolait¹, Julian F. R. Paton²,³ and Anne-Marie O’Carroll*²

¹ Faculty of Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom, ² Department of Physiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, ³ Faculty of Biomedical Sciences, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom

The central site(s) mediating the cardiovascular actions of the apelin-apelin receptor (APJ) system remains a major question. We hypothesized that the sensory circumventricular organs (CVOs), interfacing between the circulation and deeper brain structures, are sites where circulating apelin acts as a signal in the central nervous system to decrease blood pressure (BP). We show that APJ gene (aplnr) expression was elevated in the CVOs of spontaneously hypertensive rats (SHRs) compared to normotensive Wistar Kyoto (WKY) controls, and that there was a greater mean arterial BP (MABP) decrease following microinjection of [Pyr¹]apelin-13 to the CVOs of SHRs compared to WKY rats. Lentiviral APJ-specific-shRNA (LV-APJ-shRNA) was used to knockdown aplnr expression, both collectively in three CVOs and discretely in individual CVOs, of rats implanted with radiotelemeters to measure arterial pressure. LV-APJ-shRNA-injection decreased aplnr expression in the CVOs and abolished MABP responses to microinjection of [Pyr¹]apelin-13. Chronic knockdown of aplnr in any of the CVOs, collectively or individually, did not affect basal MABP in SHR or WKY rats. Moreover, knockdown of aplnr in any of the CVOs individually did not affect the depressor response to systemic [Pyr¹]apelin-13. By contrast, multiple knockdown of aplnr in the three CVOs reduced acute cardiovascular responses to peripheral [Pyr¹]apelin-13 administration in SHR but not WKY rats. These results suggest that endogenous APJ activity in the CVOs has no effect on basal BP but that functional APJ in the CVOs is required for an intact cardiovascular response to peripherally administered apelin in the SHR.

Keywords: apelin, apelin receptor (APJ), circumventricular organs (CVOs), hypertension, spontaneously hypertensive rat (SHR)

INTRODUCTION

Dysfunctions in mechanisms that regulate blood pressure (BP) participate in the development of hypertension that is mediated, in part, by activation of the sympathetic nervous system (SNS) (Zubcevic et al., 2011; Fisher and Paton, 2012) or by renal control of peripheral vascular resistance and body fluid volume (Wadei and Textor, 2012). A significant percentage of patients with essential
hypertension, that accounts for 95% of all cases of hypertension (Carretero and Oparil, 2000), exhibit chronic sympathetic hyperactivity, but the causative mechanisms remain unclear. The neuropeptide apelin (gene name apln) has well-established effects on cardiovascular and BP regulation via central and peripheral targets (O’Carroll et al., 2013) and mediates its effects via activation of the apelin receptor APJ (O'Dowd et al., 1993) (gene name aplrn). Apln encodes a 77-amino acid precursor (Tatemoto et al., 1998) that is enzymatically cleaved into several bioactive fragments, e.g., apelin-36, apelin-13, and subsequently processed into [Pyr³]apelin-13, which is the most abundant apelin isoform in the cardiovascular system (Maguire et al., 2009). APJ has highest homology to the angiotensin II receptor type AT1 and has been shown to antagonize the pressor effects of angiotensin II (Ang II) (Ishida et al., 2004; Siddiquee et al., 2013) by up-regulation of angiotensin-converting enzyme 2 (ACE2) and suppression of Ang II signaling (Sato et al., 2019). APJ and apelin are known key regulators of responses to multiple homeostatic perturbations including cardiovascular (Lee et al., 2000; Reaux et al., 2001; Seyedabadi et al., 2002; Ishida et al., 2004; Kuba et al., 2007; Kang et al., 2013; Wang et al., 2015; Yang et al., 2017), fluid (O’Carroll and Loliat, 2003), and food intake regulation (Reaux-Le Goazigo et al., 2011). The apelinergic system is implicated in cardiovascular and metabolic disease etiology and may act to mitigate the pathogenesis of heart failure and hypertension (Barnes et al., 2010) and of obesity-induced disorders that are common predisposing factors in hypertension (Dray et al., 2008; Sawane et al., 2013; O’Harte et al., 2018; Parthsarathy et al., 2018). Apelin and APJ mRNA and protein are expressed in the central nervous system (CNS), in regions such as the hypothalamic paraventricular nucleus (PVN) and the rostral ventrolateral medulla (RVLM) that participate in the control of BP, and also in a variety of peripheral organs including the pituitary gland, heart, adipose tissue, kidney, and gastrointestinal tract (O’Carroll et al., 2013). Apln expression in the PVN is up-regulated in response to acute and repeated stress (O’Carroll et al., 2003), while expression of apln is up-regulated in cardiac myocytes by hypoxia (Ronkainen et al., 2007). Insulin elevates both aplnr and apln expression, and apelin production, in adipose tissue (Sörhede Winzell et al., 2005; Dray et al., 2010). Furthermore, plasma apelin levels are increased by glucose administration (Soriguer et al., 2009) and in certain conditions such as heart failure with chronic systemic hypoxia (Ferdinal et al., 2019), and decreased by osmotic stimuli (De Mota et al., 2004). Plasma apelin concentration is also increased in insulin resistant subjects (Li et al., 2006), in type 2 diabetic (T2D) patients (Cavallo et al., 2012), and in obese individuals (Boucher et al., 2005). The peripheral apelinergic system appears to be down-regulated in hypertensive disease, with changes in the levels of both immunoreactive (ir)-APJ and/or apln/apelin in human (Sommez et al., 2010; Chandra et al., 2011; Zhu et al., 2013) and some rodent hypertension models (Zhang et al., 2006).

The cardiovascular effects of apelin differ depending on whether it is administered centrally or peripherally. Apelin activates pressor mechanisms in the brain, where direct injection into the PVN or RVLM of rats increases BP (Seyedabadi et al., 2002; Zhang et al., 2009, 2014; Griffiths et al., 2018), while the overall effect of peripherally administered apelin, which may be acting via APJ present at peripheral and/or central sites, decreases BP in multiple animal models (Lee et al., 2000; Reaux et al., 2001; Mitra et al., 2006; Siddiquee et al., 2013), with the magnitude of the depressor effect being enhanced in hypertensive animals such as the spontaneously hypertensive rat (SHR) (Lee et al., 2005). Interestingly, APJ and apelin mRNAs are expressed within the sensory circumventricular organs (CVOs) (Hatzelmann et al., 2009; Griffiths et al., 2020), comprised of the subfornical organ (SFO), organum vasculosum of lamina terminalis (OVLT), and the area postrema (AP). These anatomical sites, lacking a blood-brain barrier (BBB), have an important role in cardiovascular regulation (Cottrell and Ferguson, 2004); they act as anatomical conduits to major sympathetic regulatory centers (McKinley et al., 2001) and display a variety of efferent and afferent inter-neuronal connections that may contribute to a composite cardiovascular response (Swanson and Kuypers, 1980; Hassel et al., 2000; Cottrell and Ferguson, 2004). CVO neurons act as sensors for circulating neuropeptides such as Ang II (Sunn et al., 2003), leptin (Smith et al., 2009), and vasopressin (Smith and Ferguson, 1997), indicating an established role for these organs as sites for monitoring peripheral signals. Microinjection of apelin into the SFO decreases BP (Dai et al., 2013), a cardiovascular response similar to that seen with peripheral administration of apelin. Additionally, we have shown increased aplnr expression in the SFO of SHRs [an established and well-characterized model of hypertension (Trippodo and Frohlich, 1981)] in comparison to control Wistar Kyoto (WKY) rats (Griffiths et al., 2020), providing evidence of a likely association for SFO APJ in the pathogenesis of hypertension in the SHR. The role of the apelinergic system in CVO functions other than electrophysiological and cardiovascular responses, such as sodium and water balance, is not known.

While the sites by which circulating apelin exerts its central effects to modulate BP are undetermined, the sensory CVOs, in addition to the PVN and RVLM, may mediate the cardiovascular actions of apelin. We hypothesized that the sensory CVOs act as a link integrating the effects of circulating and central apelin on BP regulation. In this study we used RNA interference (RNAi) to examine whether down-regulation of apln expression in individual sensory CVOs, or alternatively simultaneous down-regulation of aplnr expression in three sensory CVOs in the same animal, blocks the effects of central and/or peripheral circulating apelin mediating cardiovascular responses in normotensive WKY and hypertensive SHR rats.

**MATERIALS AND METHODS**

**Ethical Approval**

All experiments were approved by the University of Bristol Animal Welfare and Ethical Review Body and performed in strict accordance with U.K. Home Office regulations [Animals (Scientific Procedures) Act (1986)].
Acute Exogenous [Pyr₁]apelin-13 Microinjection Into CVOs

To establish CVO co-ordinates and for preliminary investigation of [Pyr₁]apelin-13 pharmacology in each CVO, Wistar rats were anesthetized by intraperitoneal (i.p.) injection of sodium pentobarbital (50 mg/kg). All surgical procedures were performed under aseptic conditions under a surgical plane of anesthesia as indicated by the absence of withdrawal reflex to hindpaw pinch, which was monitored throughout the procedure and additional doses of anesthetic given as necessary. BP was monitored via a heparin-saline (1 U/ml) filled catheter (Micro-Renathane tubing, 0.8 mm inner diameter, Braintree Scientific) implanted in the left or right femoral artery and connected to a pressure transducer (BD DTX Plus, Southwest Medical, Bristol, United Kingdom). For injections to the SFO and OVLT the head was secured in a stereotaxic frame with the head held level (confirmed by bregma and lambda having the same depth coordinate). For injections to the AP the head was flexed down (nose bar at −19 mm), and the atlanto-occipital membrane pierced to allow visualization, with the aid of a binocular surgical microscope (Leica M651, United Kingdom), of the AP as a highly vascularized structure above the Obex on the midline dorsal surface of the medulla oblongata. The CVOs were targeted using previously established stereotaxic co-ordinates: OVLT: 0.4 mm rostral to bregma, 0 mm lateral to midline, 8.0 mm below dura; SFO: 1.3 mm caudal to bregma, midline, 4.5 mm below dura [differences between these levels and those depicted in the representative atlas sections in Figures 1–3 are accounted for by the age difference of our rats (∼250 g) and those (∼290 g) used to construct the reference atlas]. Injections to all structures were made using single-barreled micropipettes (1–5 µl pre-calibrated microcapillary tube, Sigma Aldrich, United Kingdom) using a binocular surgical microscope. Microinjection of Ang II (100 pmol 100 nl⁻¹; Tocris Bioscience, United Kingdom) was used to functionally confirm the position of the pipette within the CVOs by recording a rise in arterial pressure (Reaux et al., 2001). The injection volume was 100 nl. Subsequent microinjections of [Pyr₁]apelin-13 or vehicle were made at the same stereotaxic coordinates that elicited the largest Ang II pressor response (∼8–10 mmHg). The effective dose of [Pyr₁]apelin-13 was determined by a dose response course (67, 200, 600, and 1800 pmol 100 nl⁻¹; n = 6/group) measuring [Pyr₁]apelin-13-induced cardiovascular effects in the CVOs and was found to be maximally effective at 200 pmol 100 nl⁻¹ in each CVO. A subset of animals received a microinjection of Indian ink (100 nl, 1:10 dilution) at the end of the experiment to confirm the location of the stereotaxic coordinates used. After the final microinjection, rats were deeply anesthetized with sodium pentobarbital and euthanized by decapitation.

Chronic Arterial Blood Pressure Measurement

Chronic Femoral Vein Cannulation

Intravenous (i.v.) cannulas were constructed and implanted as described previously (Griffiths et al., 2018) to allow i.v. administration of pharmacological compounds. Briefly, adult WKY (n = 34) and SHR (n = 34) rats were anesthetized with isoflurane (4% for induction and 2% for maintenance in O₂) and provided with analgesia (Vetgesic; 0.8 mg kg⁻¹). Cannulas were implanted in the left femoral vein, tunneled subcutaneously, and externalized between the scapulae. Following surgery, rats were housed singly in a soundproofed room. Cannulae were flushed with 0.5 ml heparinized saline (50 IU ml⁻¹) daily for 1 week following surgery and then every other day for the remainder of the experiment.

Gene Transfer

Transfer of Viral Vectors Into the CVOs

The aphr- specific (LV-AP)-shRNA and non-targeting scrambled (LV-scr-shRNA) short hairpin RNAs (shRNAs), incorporating green fluorescent protein (GFP), were expressed in the lentiviral transfer vector pRRL.SIN.CPPT.CMV.GFP.WPRE (modified from Addgene plasmid 12252). Lentiviral particles (LV) were produced using packaging plasmids pMDLg/pRRE, pRSV-Rev and PMD2.G (Addgene) to a titer of LV-APl-shRNA, 1.12 × 10¹⁰ pfu ml⁻¹ and LV-scr-shRNA, 4.3 × 10⁹ pfu ml⁻¹ as described previously (Griffiths et al., 2018). The effective time point after virus transfection into the CVOs was determined by a time course (18 and 25 days; n = 8/group) measuring loss of [Pyr₁]apelin-13-induced cardiovascular effects in the CVOs and was found to be maximally effective at 18 days.

Intraparenchymal Injection of Lentivirus

Eleven days post telemeter implantation and after 5 days of baseline recording, WKY and SHR rats (n = 34/group) were randomly assigned to either the LV-AP-shRNA or control LV-scr-shRNA lentiviral particles group. Animals were anesthetized with an intramuscular injection of ketamine (60 mg kg⁻¹) and medetomidine (250 µg kg⁻¹), analgesia administered (Vetgesic 0.8 mg kg⁻¹), and microinjected either individually in one of the OVLT (n = 4/group), SFO (n = 6/group) or AP (n = 4/group), or
in the three CVOs simultaneously (n = 3/group), with either LV-APJ-shRNA or LV-scr-shRNA (titre > 10⁹ transforming units/ml; 1 μl). The micropipette was advanced to the correct depth for the structure of interest (using the brain coordinates outlined above) and allowed to rest for 5 min prior to viral vector (1 μl) delivery over a period of 10 min. The pipette was then left in situ for a further 5 min to minimize back-tracking of the virus. Anesthesia was reversed by a subcutaneous injection of...
antisedan (1 mg kg\(^{-1}\)). BP recording continued for 18 days (see data acquisition below).

**Terminal Experiment**

**Chronic Aplnr CVO Knockdown and Cardiovascular Responses to i.v. Administered Apelin**

Eighteen days post virus injection(s), rats were anesthetized with sodium pentobarbital (50 mg kg\(^{-1}\) i.p.) and cardiovascular parameters monitored using the implanted telemeter. [Pyr\(^1\)]apelin-13 (2 nmol/kg; 300 µl, i.v) and vehicle (saline, 300 µl, i.v.) was administered to assess any changes in apelin-induced pressor responses. Following injection, BP was allowed to recover for 30 min.

**Chronic Aplnr CVO Knockdown and Cardiovascular Responses to Central Microinjection of Apelin**

To confirm that chronic knock-down of aplnr blocked mean arterial blood pressure (MABP) responses, a direct “challenge”
FIGURE 3 | Central apelin microinjection into the AP decreases arterial blood pressure. (A) Schematic illustrating the localization of injection sites (symbols indicate injection sites) in the AP, representative of sections (level relative to bregma indicated) from each animal group, determined by examination of the deposition of dye in the brain stem of animals. In inset: 10 N, dorsal motor nucleus of vagus; AP, area postrema; CC, central canal; CeCv, central cervical nucleus of the spinal cord; Gr, gracile nucleus; SolC, nucleus of the solitary tract, commissural part; SolDL, solitary nucleus, dorsolateral part; SolIM, nucleus of the solitary tract, intermediate part; SolM, nucleus of the solitary tract, medial part; SubP, subpostrema area (adapted from Paxinos and Watson, 2005; Figure 150). (B) Representative raw traces, binned over 1 s, showing the BP response in single animals following microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1), angiotensin II (Ang II) (100 pmol 100 nl−1), and saline to the AP. The dotted line indicates the microinjection of compound. (C) Change in MABP following microinjection of saline, angiotensin II (Ang II 100 pmol, 100 nl−1) and [Pyr1]apelin-13 (200 pmol 100 nl−1) to the AP of Wistar rats (n = 6). Data is mean ± SEM with individual responses. Data analyzed with 1-way ANOVA followed by Tukey’s Multiple Comparison test. ***P < 0.001.

microinjection of [Pyr1]apelin-13 (200 pmol 100 nl−1) to the OVLT, SFO, and/or AP, similar to that described previously for the RVLM (Griffiths et al., 2018), was carried out. BP was monitored via the implanted telemeter. CVO injections followed the same protocol described above. Rats were then euthanized using a guillotine. Brains were immediately frozen on powdered dry ice and stored at −80°C to preserve RNA integrity. The level of aplnr knockdown was confirmed by quantitative PCR (qPCR) (see below).

RNA Extraction and cDNA Synthesis

Fresh, frozen sections (40 µm) were cut on a cryostat (CM3050 S, Leica Microsystems) and collected on the freezing plate. Every fifth section was stained with 0.1% toluidine blue to aid
identification of the CVOs and samples were then collected using a 1 mm diameter micropunch (Fine Scientific Tools) and placed into separate 1.5 ml RNAse/DNase-free tubes (Appleton Woods, United Kingdom) on dry ice and stored at −80°C, before RNA extraction. The protocols for RNA extraction and cDNA synthesis from brain punches have been described previously (Griffiths et al., 2018).

Real Time qPCR Analysis
Primers used and the protocol followed are as described (Griffiths et al., 2018). qRT-PCR was carried out in duplicate using SYBR green (Thermo Fisher Scientific, United Kingdom) on an ABI StepOnePlus Sequence Detection System (ABI, Warrington, United Kingdom). All qRT-PCR reactions were followed by dissociation curve analysis. For relative quantification of gene expression the 2−ΔΔCT method was employed (Livak and Schmittgen, 2001). The internal control genes used were the housekeeping genes ribosomal protein L19 (Rpl19) and glyceraldehyde 3-phosphate dehydrogenase (Gapdh).

Data Analysis
BP waveforms were captured using a CED 1401 data capture system and Spike 2.7 software (CED, United Kingdom) sampled at 2 kHz. BP waveforms were processed offline using the HRBP (version 8) script for Spike 2 in order to extract systolic (SABP), diastolic (DABP) and MABP, pulse interval (PI), respiratory rate (RR), and heart rate (HR) waveforms. For acute experiments on exogenous [Pyr1]apelin-13 microinjection into Wistar rat CVOs using pressure transducers, representative MAPB readings are shown and data is presented as change in physiological variable by subtraction of the post-microinjection response from the pre-microinjection baseline for each compound. BP data are presented as mean ± SEM and tested for statistical significance using a repeated measures 1-way ANOVA followed by Tukey’s Multiple Comparison test using Graphpad Prism 8.0 software for Mac (Graphpad Software Inc., United States). Statistical significance for differences between groups was defined as P < 0.05. Unless stated differently, statistical differences between two experimental groups were evaluated using independent-sample unpaired Student’s t-tests. Experimenter were not blinded to the conditions being analyzed.

RESULTS

Central Apelin Microinjection Into the CVOs Decreases Arterial Blood Pressure
Schematics illustrating the localization of injection sites in the OVLT, SFO, and AP in coronal sections are shown in Figures 1A, 2A, 3A, respectively. Representative raw traces from single animals showing the BP response following microinjection of [Pyr1]apelin-13, Ang II and to the OVLT, SFO, and AP are shown in Figures 1B, 2B, 3B, respectively. Microinjection of Ang II (100 pmol) into the OVLT, SFO, or AP, significantly increased MABP in the OVLT (Figure 1C), SFO (Figure 2C), and AP (Figure 3C) of Wistar rats, compared to saline-injected controls. Microinjection of [Pyr1]apelin-13 (200 pmol) into the OVLT, SFO, or AP decreased MABP (Figures 1C, 2C, 3C, respectively) compared to saline-injected controls.

Peripheral Apelin Injection Decreases Arterial Blood Pressure in SHR and WKY Rats
Baseline physiological variables in awake normotensive WKY rats and hypertensive SHRs are summarized in Table 1. Baseline MAPB was 103 ± 3 vs. 138 ± 3 mmHg in WKY

### TABLE 1 | Baseline physiological parameters measured prior to virus injection in WKY and SHR rats.

|         | WKY | SHR |
|---------|-----|-----|
|         | LV-scr-shRNA | LV-APJ-shRNA | LV-scr-shRNA | LV-APJ-shRNA |
| DABP (mmHg) | 83 ± 3 | 87 ± 5 | 106 ± 4 | 117 ± 3 |
| SABP (mmHg) | 127 ± 3 | 127 ± 5 | 169 ± 4 | 181 ± 3 |
| MABP (mmHg) | 103 ± 3 | 102 ± 5 | 138 ± 3 | 147 ± 2 |
| PP (mmHg) | 44 ± 1 | 44 ± 1 | 64 ± 1 | 64 ± 1 |
| RR (breaths/min) | 93 ± 1 | 93 ± 1 | 87 ± 1 | 88 ± 1 |
| HR (bpm) | 312 ± 5 | 314 ± 7 | 306 ± 3 | 308 ± 2 |
| Weight (g) | 246 ± 3 | 243 ± 3 | 268 ± 3 | 263 ± 2 |

Data is mean ± SEM, n = 17/group.
and SHR, respectively. Representative raw traces from single animals showing the change in MABP following i.v. injection of [Pyr$^1$]apelin-13 in WKY rats and SHRs are shown in Figure 4A. Peripheral injection of [Pyr$^1$]apelin-13 (2 nmol/kg; i.v. by femoral vein) in both WKY rats and SHRs decreased MABP and LF-SBPV (Figures 4B,C, respectively) compared to saline-injected controls. The decrease in MABP in response to i.v. [Pyr$^1$]apelin-13 was significantly greater in SHR than in WKY rats (Figure 4B).

**Apln**r Expression Is Up-Regulated in OVLT, SFO, and AP of SHR

To examine *aplnr* expression in the CVOs from normotensive and hypertensive rats, expression levels in micropunches of CVOs from WKY rats and SHRs were quantified using qPCR. *Apln*r transcript levels were higher in OVLT, SFO, and AP in SHRs in comparison with WKY control rats (Figures 4D–F, respectively).

**LV-APJ-shRNA-Injection in Individual CVOs in WKY and SHRs Decreases Apln**r Expression and Silences Cardiovascular Responses to Microinjection of [Pyr$^1$]apelin-13

Lentiviral vector-mediated gene delivery was used to knockdown *aplnr* expression in each of the OVLT, SFO, and AP individually in WKY rats and in SHRs. qPCR analysis of micropunches from the CVOs of animals microinjected...

---

**FIGURE 4** Peripheral [Pyr$^1$]apelin-13 injection decreases arterial blood pressure and SBPV in SHR and WKY rats and aplnr expression is up-regulated in the CVOs. (A) Representative raw traces showing the BP response in single animals following peripheral i.v. injection (vertical dotted line) of [Pyr$^1$]apelin-13 (2 mol/kg) and saline to WKY and SHR rats. Change in (B) MABP and (C) LF-SBPV following i.v. injection of saline and [Pyr$^1$]apelin-13 (2 mol/kg) to WKY (light gray bar, circles) and SHR (dark gray bar, triangles) rats. Data is mean ± SEM with individual responses (n = 14/group). Relative expression of aplnr in (D) OVLT, (E) SFO and (F) AP micropunches from WKY (light gray bar, circles) and SHR (dark gray bar, triangles) rats. Data is mean ± SEM with individual responses (n = 6/group). Data analyzed with Student’s unpaired t-tests. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Knockdown in Sensory CVOs with LV-APJ-shRNA confirmed successful knockdown of aplnr expression in the OVLT, SFO, or AP at day 18 post-virus injection in WKY rats (Figures 5A,E,I, respectively) and SHRs (Figures 5C,G,K, respectively) compared with those control animals injected with LV-scr-shRNA. The effectiveness of the LV-APJ-shRNA injection was additionally verified by measuring the cardiovascular responses of rats to a challenge microinjection of [Pyr]1 apelin-13 individually into each of the OVLT, SFO or AP of anesthetized WKY and SHRs at day 18 post-virus injection. For each of the OVLT,

![Graphs showing knockdown of aplnr expression and cardiovascular responses](image)

**FIGURE 5** | LV-APJ-shRNA-injection in individual CVOs in WKY and SHRs decreases aplnr expression and silences cardiovascular responses to microinjection of [Pyr]1 apelin-13. Relative aplnr expression in micropunched tissue (A,C,E,G,I,K) and change in MABP following microinjection of [Pyr]1 apelin-13 (200 pmol 100 nl−1) (B,D,F,H,J,L) 18 days following microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) to the OVLT of WKY (A,B) and SHR (C,D) rats (n = 4/group), to the SFO of WKY (E,F) and SHR (G,H) rats (n = 6/group), and to the AP of WKY (I,J) and SHR (K,L) rats (n = 4/group). Data is mean ± SEM with individual responses. Data analyzed with Student’s unpaired t-tests. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
SFO, and AP, microinjection of [Pyrr]apelin-13 decreased MABP in LV-scr-shRNA-injected WKY rats (Figures 5B,F,J, respectively) and SHRs (Figures 5D,H,L, respectively). Knockdown of aplnr in the individual CVOs by LV-APJ-shRNA-injection prevented this decrease in MABP in response to microinjection of [Pyrr]apelin-13 into the OVLT, SFO, or AP of WKY rats (Figures 5B,F,J, respectively), or SHRs (Figures 5D,H,L, respectively).

**Individual CVO-Targeted Chronic Aplnr Knockdown Does Not Block the Peripheral Depressor Effect of [Pyrr]apelin-13 in Normotensive or Hypertensive Rats**

At any point during the 18-day monitoring period, no significant difference was seen in MABP or LF-SBPV between animals transduced individually in either the OVLT, SFO, or AP with either LV-APJ-shRNA or LV-scr-shRNA in WKY rats or SHRs (Table 2). Falls in MABP induced by i.v. hexamethonium injection were similar between all OVLT, SFO, and AP LV-APJ-shRNA- or LV-scr-shRNA-injected WKY rats or SHRs (Table 2).

At day 18 post-virus injection, all groups of individual CVO-targeted WKY and SHRs were injected i.v. with [Pyrr]apelin-13 or saline control and MABP recorded. The decrease in MABP observed following peripheral administration of [Pyrr]apelin-13 was maintained despite aplnr knockdown individually in the OVLT, SFO, or AP of WKY rats or SHRs (Table 2).

Similarly, the decrease in LF-SBPV observed following peripheral administration of [Pyrr]apelin-13 was maintained despite aplnr knockdown individually in the OVLT, SFO, or AP of WKY rats or SHRs (Table 2).

**Multiple CVO-Targeted Aplnr Knockdown Does Not Block the Peripheral Depressor Effect of [Pyrr]apelin-13 in Normotensive Rats**

To elucidate whether multiple knockdown of aplnr expression simultaneously in the OVLT, SFO, and AP in the same animal affects the depressor effect of peripherally-injected [Pyrr]apelin-13, WKY rats were injected with either LV-APJ-shRNA or LV-scr-shRNA in the three CVOs. qPCR analysis of aplnr in micropunches from the OVLT, SFO, and AP showed knockdown of aplnr in WKY rats injected with LV-APJ-shRNA simultaneously into the three CVOs when compared with LV-scr-shRNA-injected rats (Figures 6A–C, respectively). A fall in MABP was seen in LV-scr-shRNA-injected WKY rats following a challenge microinjection of [Pyrr]apelin-13 separately into the OVLT, SFO, or AP (Figures 6D–F, respectively). In comparison, the decrease in MABP did not persist in LV-APJ-shRNA-injected WKY rats (Figures 6D–F, respectively). These data confirm knockdown of aplnr by LV-APJ-shRNA-injection in the three regions.

**TABLE 2** Individual OVLT-, SFO-, or AP-targeted knockdown of aplnr in WKY and SHR rats.

| Targeted CVO | WKY | SHR |
|--------------|-----|-----|
|              | LV-scr-shRNA | LV-APJ shRNA | LV-scr-shRNA | LV-APJ shRNA |
| OVT | 14.39 ± 7.54 | 16.26 ± 7.05 |
| SFO | 16.45 ± 3.01 | 10.72 ± 1.64 |
| AP  | 9.94 ± 1.22 | 17.45 ± 2.24 |
| OVT | 2.08 ± 0.60 | 3.92 ± 0.70 |
| SFO | 2.58 ± 1.51 | 4.62 ± 1.58 |
| AP  | 2.82 ± 1.18 | 2.83 ± 0.88 |
| OVT | 14.95 ± 1.32 | 20.63 ± 1.16 |
| SFO | 18.80 ± 4.10 | 17.60 ± 1.17 |
| AP  | 20.63 ± 1.16 | 23.54 ± 1.62 |
| OVT | 8.24 ± 0.98 | 16.24 ± 2.97 |
| SFO | 18.14 ± 2.11 | 18.14 ± 2.11 |
| AP  | 20.74 ± 4.78 | 20.74 ± 4.78 |
| OVT | 5.01 ± 0.97 | 4.46 ± 1.41 |
| SFO | 5.45 ± 1.57 | 5.45 ± 1.57 |
| AP  | 5.89 ± 1.15 | 8.74 ± 2.26 |

Individual OVLT- (n = 4/group), SFO- (n = 6/group), or AP-targeted (n = 4/group) knockdown of aplnr in WKY or SHR rats had no effect on chronic MABP (mm Hg), chronic LF-SBPV (% total power), hexamethonium-induced falls in MABP (mm Hg), the peripheral depressor effect of [Pyrr]apelin-13 (mm Hg) or the peripheral-induced decrease in LF-SBPV (% total power). Data is mean ± SEM.
Simultaneous CVO-targeted aplnr knockdown does not block the peripheral depressor effect of [Pyr<sup>1</sup>]apelin-13 in WKY rats. Relative aplnr expression in the OVLT (A), SFO (B), and AP (C), and change in MABP following microinjection of [Pyr<sup>1</sup>]apelin-13 (200 pmol 100 nl<sup>−1</sup>−1) in the OVLT (D), SFO (E), and AP (F). 18 days following microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) simultaneously to the OVLT, SFO, and AP of WKY rats (n = 3/group). Data is mean ± SEM with individual responses. Data in (A–F) analyzed with Student’s unpaired t-tests, *P < 0.05, **P < 0.01.

(G) Changes in MABP ranging from 5 days before (−5) to 18 days after microinjection (vertical dotted line) of either LV-scr-shRNA (gray line) or LV-APJ-shRNA (black line) simultaneously to the OVLT, SFO, and AP of WKY rats (n = 3/group). Inset bar graph shows change in MABP calculated as MABP at day -5 subtracted from MABP at day 17.

(H) Change in LV-SBPV after microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares), calculated as LF-SBPV at day -5 subtracted from LF-SBPV at day 17 (n = 3/group).

(I) Change in MABP following hexamethonium (10 mg kg<sup>−1</sup>, i.v.) injection at day 16 post LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) injection (n = 3/group).

(J) Representative raw traces showing changes in MABP in single animals in response to i.v. [Pyr<sup>1</sup>]apelin-13 (black symbols, 2 mol/kg) or saline (gray symbols) in WKY rats injected simultaneously in the OVLT, SFO, and AP with either LV-APJ-shRNA (squares) or LV-scr-shRNA (circles). Change in MAPB (K) and LV-SBPV (L) following peripheral administration of [Pyr<sup>1</sup>]apelin-13 (2 nmol kg<sup>−1</sup>) to WKY rats (n = 3/group) 18 days post-injection in the OVLT, SFO, and AP with either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares). Data in panels (G–L) is mean ± SEM with individual responses and analyzed with Student’s unpaired t-tests.
The mechanisms by which peripheral and central apelin modulates BP remains a major question. For example, whether blood-borne apelin acts at the same locus as centrally synthesized apelin is unknown and indeed the neuronal circuitry expressing apelin is not fully understood. The present study examines the role of APJ in the sensory CVOs for regulation of arterial pressure in SHR and WKY rats. We reveal a number of novel findings. First, aplnr is up-regulated in the OVLT, SFO, and AP in SHRs in comparison to WKY rats. Second, microinjection of [Pyr\(^1\)]apelin-13, acting via APJ, into any of the three CVOs decreases MABP and this is greater in the SHR. Third, knockdown of aplnr in the CVOs, either collectively or individually, affects neither resting MABP nor an indirect measure of sympathetic nerve activity. Fourth, aplnr in the three CVOs collectively modulates the acute cardiovascular responses to systemic apelin in hypertensive SHRs but not in normotensive WKY rats. In SHRs, knockdown of aplnr in the three sensory CVOs collectively, but not in any CVO individually, reduces both the depressor and SBPV responses to peripheral [Pyr\(^1\)]apelin-13 administration.

Our data demonstrates that aplnr is expressed in the CVOs, where the lack of a BBB may facilitate the interaction of circulating apelin with APJ present in these structures. Aplnr is up-regulated in the OVLT, SFO, and AP of SHRs in comparison to WKY rats, consistent with our earlier study showing increased aplnr expression in the SFO of SHRs (Griffiths et al., 2020) and with other studies showing an up-regulated aplnr expression in the PVN and RVLM of SHRs (Zhang et al., 2014; Griffiths et al., 2018). It is currently unknown whether these changes in aplnr levels correspond to changes in levels of functional protein, however, we have shown an augmented depressor response to microinjection of [Pyr\(^1\)]apelin-13 in the SHR CVOs in comparison to WKY rats, that supports raised APJ expression in the SHR. The factors that drive increased aplnr expression in the SHR CVOs are not known. The up-regulation in gene expression may be compensatory and contribute to the effect of apelin given peripherally. Such compensatory changes (e.g., remodeling of microvascular and glial cells (Ritz et al., 2009) with possible alterations of aplnr levels in these cells) may have consequences for the activity of CVO efferent projections, and may help modulate BP in the face of hypertension. It is unknown whether the higher resting sympathetic tone of SHRs (Iriuchijima, 1973; Judy et al., 1976) contributes to the more pronounced BP responses to CVO [Pyr\(^1\)]apelin-13 microinjection observed in SHRs. Apelinergic gene expression levels are altered in conditions of hypertension, e.g., myocardium aplnr/apoln levels are down-regulated in experimental heart failure in Dahl salt-sensitive rats (Iwanaga et al., 2006) and decreased aplnr/apoln levels are seen in the heart and aorta of SHRs compared to normotensive rats (Zhong et al., 2005), while aplnr/apoln levels and apelin/APJ protein are up-regulated in the PVN of SHR (Zhang et al., 2014), reflecting a differential peripheral vs. central expression pattern. Additionally, circulating levels of apelin are decreased in chronic heart failure (Földes et al., 2003) and in essential and pulmonary hypertension (Sonmez et al., 2010; Chandra et al., 2011), and increased in disease states such as aortic stenosis (Duman et al., 2018), and left ventricular hypertrophy (Helske et al., 2010). These findings highlight the importance of understanding the physiological and pathophysiological roles of central and peripheral apelin in cardiovascular control.

We have previously shown our APJ-specific shRNA viral vector is successful in in vivo knockdown of central aplnr in the rat RVLM (Griffiths et al., 2018), with transgene expression

**DISCUSSION**

Body weights did not differ between LV-APJ-shRNA- and LV-scr-shRNA-transduced WKY groups over the monitoring period (Table 1). Resting MABP (Figure 6G and insert) and LF-SBPV (Figure 6H) were unchanged in LV-APJ-shRNA-injected rats compared to LV-scr-shRNA-injected rats over the 18 day monitoring period. No change was seen in hexamethonium-induced falls in MABP between animals injected with LV-APJ-shRNA- or LV-scr-shRNA in the OVLT, SFO, and AP (Figure 6I). Representational raw traces of MABP following administration of i.v. [Pyr\(^1\)]apelin-13 or saline in single WKY rats with multiple CVO aplnr knockdowns at day 18 post-virus injection are shown in Figures 6J. Peripheral i.v injection of [Pyr\(^1\)]apelin-13 in LV-scr-shRNA WKY rats decreased MABP (Figure 6K) and LV-SBPV (Figure 6L). The decrease in both MABP and LV-SBPV persisted in LV-APJ-shRNA-injected WKY rats despite knockdown of aplnr in the 3 sites (Figures 6K,L, respectively).

**Multiple CVO-Targeted Aplnr Knockdown Attenuates the Peripheral Depressor Effect of [Pyr\(^1\)]apelin-13 in Hypertensive Rats**

At 18-days post shRNA-injection, qPCR evaluation of micropunched OVLT, SFO, and AP tissues confirmed knockdown of aplnr (Figures 7A–C, respectively), and the expected decrease in MABP following microinjection of [Pyr\(^1\)]apelin-13 onto the OVLT, SFO, and AP was prevented (Figures 7D–F, respectively) in multiple CVO-targeted LV-APJ-shRNA-injected SHRs in comparison to LV-scr-shRNA-injected SHRs. No change was observed in MABP (Figure 7G and insert) and LF-SBPV (Figure 7H) between LV-APJ-shRNA-injected and LV-scr-shRNA-injected SHRs over the 18 day observation period after aplnr knockdown in all three CVO structures. Additionally, no change was seen in hexamethonium-induced falls in MABP between SHRs injected concurrently with LV-APJ-shRNA- or LV-scr-shRNA in all three sensory CVOs (Figure 7I). Representative raw traces showing changes in MABP in response to i.v. [Pyr\(^1\)]apelin-13 or saline administration in single SHRs simultaneously injected in the OVLT, SFO, and AP with either LV-scr-shRNA or LV-APJ-shRNA are shown (Figure 7J). Peripheral i.v injection of [Pyr\(^1\)]apelin-13 in LV-scr-shRNA-injected SHRs decreased both MABP (Figure 7K) and LV-SBPV (Figure 7L) at day 18 post-shRNA injection. This decrease in MABP and LF-SBPV was significantly attenuated (Figures 7K,L, respectively) in SHRs with multiple CVO-targeted knockdown of aplnr in the same animal by LV-APJ-shRNA-injection.
FIGURE 7 | Simultaneous CVO-targeted aplnr knockdown attenuates the peripheral depressor effect of [Pyr]\(^1\)apelin-13 in SHRs. Relative aplnr expression in the OVLT (A), SFO (B), and AP (C), and change in MAPB following microinjection of [Pyr]\(^1\)apelin-13 (200 pmol/100 nl\(^-\)1) in the OVLT (D), SFO (E), and AP (F), 18 days following microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) simultaneously to the OVLT, SFO, and AP of SHRs (n = 3/group). Data is mean ± SEM with individual responses. Data in panels (A–F) analyzed with Student’s unpaired t-tests, *P < 0.05, **P < 0.01, ***P < 0.001.

(G) Changes in MAPB ranging from 5 days before (-5) to 18 days after microinjection (vertical dotted line) of either LV-scr-shRNA (gray line) or LV-APJ-shRNA (black line) simultaneously to the OVLT, SFO, and AP of SHRs (n = 3/group). Inset bar graph shows change in MAPB calculated as MAPB at day -5 subtracted from MAPB at day 17. (H) Change in LV-SBPV after microinjection of either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares), calculated as LV-SBPV at day -5 subtracted from LV-SBPV at day 17 (n = 3/group). (I) Change in MAPB following hexamethonium (10 mg kg\(^-\)1, i.v.) injection at day 16 post LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares) injection (n = 3/group). (J) Representative raw traces showing changes in MAPB in single animals in response to i.v. [Pyr]\(^1\)apelin-13 (black symbols, 2 mol kg\(^-\)1) or saline (gray symbols) in WKY rats injected simultaneously in the OVLT, SFO, and AP with either LV-APJ-shRNA- (squares) or LV-scr-shRNA- (circles). Change in MAPB (K) and LV-SBPV (L) following peripheral administration of [Pyr]\(^1\)apelin-13 (2 nmol/kg) to SHRs (n = 3/group) 18 days post-injection in the OVLT, SFO, and AP with either LV-scr-shRNA (light gray bar, circles) or LV-APJ-shRNA (dark gray bar, squares). Data in panels (G–L) is mean ± SEM with individual responses and analyzed with Student’s unpaired t-tests, *P < 0.05.
highly expressed 3 weeks after transfection. Using the same construct in the present study, we established CVO knockdown of *aplnr* in all LV-APJ-shRNA-injected rats. This was confirmed both by qPCR analysis showing efficient LV-APJ-shRNA-induced suppression of CVO *aplnr* expression and also by subsequent loss of functionality, i.e., loss of APJ CVO depressor response to apelin in vivo after microinjection of exogenous [Pyr<sup>1</sup>]apelin-13 into the CVO, in knockdown animals, demonstrating robust and reliable reduction of central apelin-mediated cardiovascular effects in the CVOs by LV-APJ-shRNA.

To investigate the role of *aplnr* in specific sensory CVOs as potential sites influencing the effects of central and/or peripheral apelin on BP regulation, we initially targeted knockdown of *aplnr* in individual CVOs in both SHRs and WKY rats. We show that chronic decreased *aplnr* expression in any individual CVO after LV-APJ-shRNA microinjection did not result in a decrease of MABP, or in sympathoinhibition (measured indirectly using power spectral analysis and hexamethonium), in normotensive or hypertensive rats when compared to control LV-scr-shRNA-injected rats. We also investigated the effect of *aplnr* knockdown on the cardiovascular responses to peripherally administered apelin. This protocol represents physiological conditions, where injected apelin has access to peripheral APJ and to receptors present in the CVOs as well, perhaps, in other brain regions—e.g., at the BBB where APJ is expressed in vascular cells and astrocytes. Apelin injected i.p. has been shown to increase hypothalamic (Higuchi et al., 2007) and cerebrospinal fluid (Sin and Bülbül, 2021) apelin levels, and to activate c-Fos in the PVN (Takeyama et al., 2008) and CVO (Sin and Bülbül, 2021), indicating that systemic apelin may be able to cross the BBB to stimulate central neurons. Based on studies of many peptides it is unlikely that polar substances such as apelin-13 and larger apelin fragments would cross the BBB by diffusion but may enter the brain parenchyma via carrier-mediated and/or receptor mediated transport (Lee and Jayant, 2019). We demonstrate that 18 days after LV-APJ-shRNA injection into individual CVOs, the decrease in BP and LF-SBPV observed following peripheral administration of [Pyr<sup>1</sup>]apelin-13 was maintained despite *aplnr* knockdown in the CVO. Our results suggest that endogenous APJ activity in individual CVOs has no effect on basal control of BP and that silencing of *aplnr* in the OVLT, SFO or AP individually does not modify the peripheral depressor effect of [Pyr<sup>1</sup>]apelin-13.

To clarify the role of *aplnr* in the CVOs on BP regulation, we then investigated the BP effects of chronic *aplnr* knockdown in three CVOs simultaneously in normotensive and hypertensive rats. Knockdown of *aplnr* in three CVOs in the same animals did not have a significant effect on BP or on indirect measure of sympathoinhibition monitored over 18 days, indicating an absence of endogenous apelin-mediated cardiovascular regulation. In contrast to tonic control of BP, we report acute effects on both MABP and indirectly measured sympathetic activity in response to exogenous application of [Pyr<sup>1</sup>]apelin-13 after simultaneous CVO *aplnr* knockdown in SHRs. In SHRs, but not in WKY rats, 18 days after *aplnr*-specific virus injection, simultaneous knockdown of *aplnr* in three CVO structures caused an immediate attenuation in the depressor effect, and in LF-SBPV, normally seen in response to peripherally administered [Pyr<sup>1</sup>]apelin-13. This suggests that functional APJ is required in the CVOs for an intact cardiovascular response to peripherally administered apelin in the hypertensive animal model used in this study. Thus, it appears that in physiological conditions apelin does not act in the CVOs to maintain baseline MABP, but when circulating apelin is increased the integrity of *aplnr* in the CVOs may be essential for a conventional BP response to apelin. An increase of apelin in the circulation, acting upon increased levels of APJ in the CVOs, may regulate sympathetic outflow by stimulating descending neural pathways, additionally offering therapeutic potential for APJ agonism in pathophysiological conditions. It is important to note that the central circuitry of APJ-expressing cell bodies and APJ-projecting fibers in either rodents or humans has not been detailed.

In our study, if APJ in one of the sensory CVOs was solely responsible for responding to changing levels of circulating apelin and transmitting this information to autonomic control centers to regulate BP, then knockdown of *aplnr* in that discrete CVO should have resulted in a change in the BP response to peripherally administered [Pyr<sup>1</sup>]apelin-13. The sensory CVOs are known to operate in a system of functional redundancy (McKinley et al., 2019) and of reciprocity of communication with regions of the cerebral cortex that regulate autonomic function (Menani et al., 2014), so it is reasonable to speculate that the loss of functional APJ integrity in one CVO may be compensated for by the remaining CVOs. By contrast, SHRs with *aplnr* CVO knockdown in three CVOs exhibited a significant deficit in the depressor response to peripheral [Pyr<sup>1</sup>]apelin-13, and in an interesting corollary, this deficit is linked to an attenuation of the spectral activity response in these rats, an indirect marker of sympathetic tone. Our findings indicate that multiple CVO *aplnr* knockdown eliminates redundancy in these central structures. The sensory CVOs are not the sole sites of action through which circulating apelin modulates pathways involved in BP regulation as silencing of CVO APJ activity did not completely abolish BP and LV-SBPV responses to [Pyr<sup>1</sup>]apelin-13 administration; however, our data indicates that the CVOs play key roles in this process. To our knowledge the combinatorial importance of the sensory CVOs in the cardiovascular response to other peripherally administered neuropeptides in vivo has not been reported.

CVOs such as the SFO, OVLT, and AP exhibit considerable transcriptomic plasticity in response to experimental manipulations including thirst (Hindmarch et al., 2008, 2011; Pool et al., 2020), food deprivation (Hindmarch et al., 2008), or early life overnutrition (Peterson et al., 2018). Some of this plasticity is contributed by vascular elements (Morita et al., 2015). *Aplnr* is expressed in neurons, glia and vascular endothelial cells in the brain (Zhang et al., 2016; Griffiths et al., 2020). Gene-targeted [e.g., single-cell fluorescence in situ hybridization (FISH)] or global (e.g., single-cell RNAseq) transcriptomic studies will allow the assessment of the contribution of different *aplnr*-expressing CVO cell types in response to elevated BP. Such studies will also shed light on whether APJ potentially interacts with other receptors in the CVOs, most notably ones, like the
angiotensin AT1 receptor, with which it has been shown to heterodimerize in vitro (Chun et al., 2008).

In summary, we have shown a significant role for APJ in the CVOs in the regulation of acute cardiovascular responses to systemic apelin in SHR. Importantly, this study has demonstrated the functional significance of APJ in the SFO, OVLT, and AP collectively as a primary feedback interface between circulating apelin and critical cardiovascular control centers that drive SNA activity to regulate BP. Central apelinergic pathways may be recruited to buffer the peripheral effects of apelin, working in a coordinated fashion to maintain BP within normal physiological limits. Understanding the central circuitry through which systemic apelin affects central cardiovascular responses will increase our understanding of the pathogenesis of hypertension and aid in elucidating the therapeutic potential of the apelinergic pathway in a hypertensive disease state.

### DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

### REFERENCES

Barnes, G., Japp, A. G., and Newby, D. E. (2010). Translational promise of the apelin-APJ system. Heart 96, 1011–1016. doi: 10.1136/hrt.2009.203456.11

Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigné, C., Mazzucotelli, A., et al. (2005). Apelin, a newly identified adipokine up-regulated by insulin and obesity. *Endocrinology* 146, 1764–1771. doi: 10.1210/en.2004-1427

Carretero, O. A., and Oparil, S. (2004). Sensory circumventricular organs: Part I: definition and etiology. *Circulation* 101, 329–335. doi: 10.1161/01.cir.101.3.329

Cavallo, M. G., Sentinelli, F., Barchetta, I., Costantino, C., Incani, M., Perra, L., et al. (2012). Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. *PLoS One* 7:e51236. doi: 10.1371/journal.pone.0051236

Dray, C., Knauf, C., Daviaud, D., Waget, A., Boucher, J., Buléon, M., et al. (2008). Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. *Cell Metab.* 8, 437–445. doi: 10.1016/j.cmet.2008.10.003

Duman, H., Bağcı, İ., Hamur, H., Demirelli, S., Ramazan Dilek, A., Erdogan, T., et al. (2018). The relationship between serum apelin levels and the severity of calcific aortic stenosis. *Acta Cardiol. Sin.* 34, 259–266. doi: 10.6515/ACS.201805.34(3).20180207A

Ferdinand, F., Limanand, D., Rini, R. D., Alexandro, R., and Helmi, R. (2019). Elevated levels of apelin-36 in heart failure due to chronic systemic hypoxia. *Int. J. Angiol.* 28, 194–199. doi: 10.1055/s-0038-1676340

Fishier, J. P., and Paton, J. F. R. (2012). The sympathetic nervous system and blood pressure in humans: implications for hypertension. *J. Hum. Hypertens.* 26, 463–475. doi: 10.1038/jhh.2011.66

Földés, G., Horkay, F., Szokodi, I., Vuolteenaho, O., Ilves, M., Lindstedt, K. A., et al. (2003). Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. *Biochem. Biophys. Res. Commun.* 308, 480–485. doi: 10.1016/s0006-291x(03)01424-4

Griffiths, P. R., Lolait, S. J., Bijabhai, A., O’Carroll-Lolait, A., Paton, J. F. R., and O’Carroll, A.-M. (2020). Increased apelin receptor gene expression in the subfornical organ of spontaneously hypertensive rats. *PLoS One* 15:e0231844. doi: 10.1371/journal.pone.0231844

### ETHICS STATEMENT

The animal study was reviewed and approved by the University of Bristol Animal Welfare and Ethical Review Body.

### AUTHOR CONTRIBUTIONS

A-MO’C, SL, and JP were responsible for acquisition of funding. A-MO’C, PG, JP, and SL contributed to the conception, design of the research, edited, and revised the manuscript. PG performed experiments. A-MO’C, SL, and PG interpreted results of the experiments. A-MO’C and PG drafted the manuscript. All authors have approved the final version of the manuscript and agreed to be accountable for all aspects of the work. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

### FUNDING

The work was supported by funding from the British Heart Foundation (PG/15/14/31311). JP was funded by the Health Research Council of New Zealand and acknowledges the support of the Sidney Taylor Trust.
Ronkainen, V. P., Ronkainen, J. J., Hänninen, S. L., Leskinen, H., Ruas, J. L., Pereira, T., et al. (2007). Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 21, 1821–1830. doi: 10.1096/fj.06-7294com
Sato, T., Kadowaki, A., Suzuki, T., Ito, H., Watanabe, H., Imai, Y., et al. (2019). Loss of apelin augments angiotensin II-induced cardiac dysfunction and pathological remodeling. Int. J. Mol. Sci. 20:239. doi: 10.3390/ijms20020239
Sawane, M., Kajiya, K., Kidoya, H., Takagi, M., Muramatsu, F., and Takakura, N. (2013). Apelin inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity. Diabetes 62, 1970–1980. doi: 10.2337/db12-0604
Seyedabadi, M., Goodchild, A. K., and Pilowsky, P. M. (2002). Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure and respiration. Auton. Neurosci. 101, 32–38. doi: 10.1016/s1566-0702(02)00178-9
Siddiquee, K., Hampton, J., McAnally, D., May, L., and Smith, L. (2013). The apelin-13 receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br. J. Pharmacol. 168, 1104–1117. doi: 10.1111/j.1476-5381.2012.02192.x
Sinjen, O., and Bülbül, M. (2021). The role of autonomic pathways in peripheral apelin-induced gastrointestinal dysmotility: involvement of the circumventricular organs. Exp. Physiol. 106, 475–485. doi: 10.1113/EP089182
Smith, P. M., and Ferguson, A. V. (1997). Vasopressin acts in the subfornical organ to decrease blood pressure. Neuroendocrinology 66, 130–135. doi: 10.1159/000127230
Smith, P. M., Chambers, A. P., Price, C. J., Ho, W., Hopf, C., Sharkey, K. A., et al. (2009). The subfornical organ: a central nervous system site for actions of circulating leptin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R512–R520. doi: 10.1152/ajpregu.09058.2008
Sommez, A., Celebìn, G., Erdem, G., Tapan, S., Genc, H., Tasci, I., et al. (2010). Plasma apelin and ADMA levels in patients with essential hypertension. Clin. Exp. Hypertens. 32, 179–183. doi: 10.3109/10641960903254505
Sörhede Winzell, M., Magnusson, C., and Ahrén, B. (2005). The apj receptor is inhibited by apelin-13 and APJ in paraventricular nucleus contribute to hypertension via sympathetic activation and vasopressin release in SHR. Acta Physiol. 212, 17–27. doi: 10.1111/j.1101-2924.2012.12342.x
Zhang, J., Ren, C. X., Qi, Y. F., Lou, L. X., Chen, L., Zhang, L. K., et al. (2006). Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci. 79, 1153–1159. doi: 10.1016/j.lfs.2006.03.040
Zhang, Q., Yao, F., Raizada, M. K., O’Rourke, S. T., and Sun, C. (2009). Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ. Res. 104, 1421–1428. doi: 10.1161/CIRCRESAHA.108.192302
Zhang, Y., Sloan, S., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., et al. (2016). Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron 89, 37–53. doi: 10.1016/j.neuron.2015.11.013
Zhang, J. C., Huang, D. Y., Liu, G. F., Jin, H. Y., Yang, Y. M., Li, Y. F., et al. (2005). Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc. Res. 65, 743–750. doi: 10.1016/j.cardiores.2004.10.020
Zhu, P., Huang, F., Lin, F., Yuan, Y., Chen, F., and Li, Q. (2013). Plasma apelin levels, blood pressure and cardiovascular risk factors in a coastal Chinese population. Ann. Med. 45, 494–498. doi: 10.3109/07853890.2013.833767
Zubcevic, J., Waki, H., Raizada, M. K., and Paton, J. F. (2011). Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension 57, 1026–1033. doi: 10.1161/HYPERTENSIONAHA.111.169748

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyrigh © 2021 Griffiths, Lolait, Paton and O’Carroll. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.